Skip to main content
Journal of Medical Ethics logoLink to Journal of Medical Ethics
. 2002 Dec;28(6):373–376. doi: 10.1136/jme.28.6.373

Consent to open label extension studies: some ethical issues

P Wainwright
PMCID: PMC1757098  PMID: 12468657

Abstract

A frequent feature of pharmaceutical research is the open label extension study, in which patients participating in double blind placebo controlled trials of new medications are invited, on completion of the initial trial, to take the study drug for some further period. Patients are openly given the active substance at this stage, regardless of their assignment in the initial trial. Investigators are typically reluctant to unblind the patients' assignment at the point of entry into the open label phase, on the grounds that this may introduce ascertainment bias in the main study.

It is argued that patients invited to participate in open label extension studies cannot give a proper consent to such research unless they know to which arm of the main trial they were recruited. It is further argued that to recruit certain groups of patients from placebo controlled trials into open label extension studies may also be unethical for clinical reasons.

Full Text

The Full Text of this article is available as a PDF (80.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Gordijn B. The troublesome concept of the person. Theor Med Bioeth. 1999 Aug;20(4):347–359. doi: 10.1023/a:1009990632439. [DOI] [PubMed] [Google Scholar]
  2. Hróbjartsson A., Gøtzsche P. C. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med. 2001 May 24;344(21):1594–1602. doi: 10.1056/NEJM200105243442106. [DOI] [PubMed] [Google Scholar]
  3. Kupfer David J., Frank Ellen. Placebo in clinical trials for depression: complexity and necessity. JAMA. 2002 Apr 10;287(14):1853–1854. doi: 10.1001/jama.287.14.1853. [DOI] [PubMed] [Google Scholar]
  4. Lewis John A., Jonsson Bertil, Kreutz Gottfried, Sampaio Cristina, van Zwieten-Boot Barbara. Placebo-controlled trials and the Declaration of Helsinki. Lancet. 2002 Apr 13;359(9314):1337–1340. doi: 10.1016/S0140-6736(02)08277-6. [DOI] [PubMed] [Google Scholar]
  5. Macklin R. The ethical problems with sham surgery in clinical research. N Engl J Med. 1999 Sep 23;341(13):992–996. doi: 10.1056/NEJM199909233411312. [DOI] [PubMed] [Google Scholar]
  6. Walsh B. Timothy, Seidman Stuart N., Sysko Robyn, Gould Madelyn. Placebo response in studies of major depression: variable, substantial, and growing. JAMA. 2002 Apr 10;287(14):1840–1847. doi: 10.1001/jama.287.14.1840. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Medical Ethics are provided here courtesy of BMJ Publishing Group

RESOURCES